United Therapeutics (NASDAQ:UTHR) CEO Sells $5,216,925.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $549.15, for a total value of $5,216,925.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,247,713.95. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Down 0.3%

Shares of UTHR stock traded down $1.48 during trading hours on Tuesday, hitting $548.09. 595,791 shares of the company’s stock were exchanged, compared to its average volume of 479,066. The firm has a market cap of $23.27 billion, a P/E ratio of 20.23, a P/E/G ratio of 1.78 and a beta of 0.57. The firm has a 50 day moving average of $566.45 and a two-hundred day moving average of $522.10. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the company earned $6.63 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on UTHR. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Finally, Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC purchased a new stake in United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics during the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.